Shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) have received an average broker rating score of 0.00 () from the three analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and two have given a strong buy recommendation to the company.
Brokerages have set a 1-year consensus price objective of $18.50 for the company, according to Zacks. Zacks has also given Aeglea Bio Therapeutics an industry rank of 148 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research lowered Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 10th.
In related news, major shareholder Orbimed Advisors Llc acquired 109,300 shares of the stock in a transaction on Tuesday, February 21st. The shares were acquired at an average price of $5.16 per share, for a total transaction of $563,988.00. The purchase was disclosed in a filing with the SEC, which is available at this link.
Several hedge funds and other institutional investors have recently made changes to their positions in AGLE. Norges Bank acquired a new position in shares of Aeglea Bio Therapeutics during the fourth quarter valued at $275,000. Perceptive Advisors LLC acquired a new position in shares of Aeglea Bio Therapeutics during the fourth quarter valued at $451,000. Alyeska Investment Group L.P. increased its position in shares of Aeglea Bio Therapeutics by 9.2% in the fourth quarter. Alyeska Investment Group L.P. now owns 119,707 shares of the company’s stock valued at $521,000 after buying an additional 10,062 shares during the last quarter. Sio Capital Management LLC increased its position in shares of Aeglea Bio Therapeutics by 8.8% in the third quarter. Sio Capital Management LLC now owns 154,332 shares of the company’s stock valued at $989,000 after buying an additional 12,458 shares during the last quarter. Finally, Baker BROS. Advisors LP acquired a new position in shares of Aeglea Bio Therapeutics during the third quarter valued at $2,591,000. 43.85% of the stock is owned by institutional investors and hedge funds.
var userip;Your IP Address: document.write(userip);
Aeglea Bio Therapeutics (NASDAQ:AGLE) opened at 8.03 on Tuesday. Aeglea Bio Therapeutics has a 12-month low of $3.66 and a 12-month high of $12.75. The stock’s market capitalization is $107.84 million. The company has a 50 day moving average of $5.51 and a 200-day moving average of $5.80.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.